1.Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ, Hu PY, Miller JK, Gerber MA, Sampliner RE et al: The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. The New England journal of medicine 1992, 327(27):1899–1905.
2.Su SY, Chiang CJ, Yang YW, Lee WC: Secular trends in liver cancer incidence from 1997 to 2014 in Taiwan and projection to 2035: An age-period-cohort analysis. Journal of the Formosan Medical Association = Taiwan yi zhi 2019, 118(1 Pt 3):444–449.
3.Chen CJ, Liang KY, Chang AS, Chang YC, Lu SN, Liaw YF, Chang WY, Sheen MC, Lin TM: Effects of hepatitis B virus, alcohol drinking, cigarette smoking and familial tendency on hepatocellular carcinoma. Hepatology (Baltimore, Md) 1991, 13(3):398–406.
4.Yeh MM, Daniel HD-J, Torbenson M: Hepatitis C-associated hepatocellular carcinomas in non-cirrhotic livers. Modern Pathology 2009, 23:276.
5.Degos F, Christidis C, Ganne-Carrie N, Farmachidi JP, Degott C, Guettier C, Trinchet JC, Beaugrand M, Chevret S: Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut 2000, 47(1):131–136.
6.Cheng ASL, Chan HLY, Leung WK, To KF, Go MYY, Chan JYH, Liew CT, Sung JJY: Expression of HBx and COX–2 in chronic hepatitis B, cirrhosis and hepatocellular carcinoma: implication of HBx in upregulation of COX–2. Modern Pathology 2004, 17:1169.
7.Ansara AJ, Nisly SA, Arif SA, Koehler JM, Nordmeyer ST: Aspirin dosing for the prevention and treatment of ischemic stroke: an indication-specific review of the literature. The Annals of pharmacotherapy 2010, 44(5):851–862.
8.Johnson ES, Lanes SF, Wentworth CE, 3rd, Satterfield MH, Abebe BL, Dicker LW: A metaregression analysis of the dose-response effect of aspirin on stroke. Archives of internal medicine 1999, 159(11):1248–1253.
9.Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, Warlow C, Hafner B, Thompson E, Norton S et al: Randomised trial of prophylactic daily aspirin in British male doctors. British medical journal (Clinical research ed) 1988, 296(6618):313–316.
10.Pignone M, Williams CD: Aspirin for primary prevention of cardiovascular disease in diabetes mellitus. Nature Reviews Endocrinology 2010, 6:619.
11.Friis S, Sorensen HT, McLaughlin JK, Johnsen SP, Blot WJ, Olsen JH: A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin. British journal of cancer 2003, 88(5):684–688.
12.Huang WK, Chiou MJ, Yu KH, Lin YC, Yang TS, Chen JS, Kuo CF, See LC: The association between low-dose aspirin use and the incidence of colorectal cancer: a nationwide cohort study. Alimentary pharmacology & therapeutics 2013, 38(4):432–439.
13.Lin CC, Lai MS, Shau WY: Can aspirin reduce the risk of colorectal cancer in people with diabetes? A population-based cohort study. Diabetic medicine: a journal of the British Diabetic Association 2015, 32(3):324–331.
14.Flossmann E, Rothwell PM: Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet (London, England) 2007, 369(9573):1603–1613.
15.Jiang HY, Huang TB, Xu L, Yu J, Wu Y, Geng J, Yao XD: Aspirin use and lung cancer risk: a possible relationship? Evidence from an updated meta-analysis. PloS one 2015, 10(4):e0122962.
16.Lapi F, Levi M, Simonetti M, Cancian M, Parretti D, Cricelli I, Sobrero A, Cricelli C: Risk of prostate cancer in low-dose aspirin users: A retrospective cohort study. International journal of cancer 2016, 139(1):205–211.
17.Jayaprakash V, Rigual NR, Moysich KB, Loree TR, Nasca MA, Menezes RJ, Reid ME: Chemoprevention of head and neck cancer with aspirin: a case-control study. Archives of otolaryngology—head & neck surgery 2006, 132(11):1231–1236.
18.Pang Q, Jin H, Qu K, Man Z, Wang Y, Yang S, Zhou L, Liu H: The effects of nonsteroidal anti-inflammatory drugs in the incident and recurrent risk of hepatocellular carcinoma: a meta-analysis. OncoTargets and therapy 2017, 10:4645–4656.
19.Ma J, Cai Z, Wei H, Liu X, Zhao Q, Zhang T: The anti-tumor effect of aspirin: What we know and what we expect. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2017, 95:656–661.
20.Yin P, Zhang L: Aspirin inhibits hepatitis C virus entry by downregulating claudin–1. Journal of viral hepatitis 2016, 23(1):62–64.
21.Hwang IC, Chang J, Kim K, Park SM: Aspirin Use and Risk of Hepatocellular Carcinoma in a National Cohort Study of Korean Adults. Scientific reports 2018, 8(1):4968.
22.Aiolfi R, Sitia G: Emerging role of dual antiplatelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma. Journal of hepatocellular carcinoma 2014, 1:183–186.
23.Pol S, Lagaye S: The remarkable history of the hepatitis C virus. Genes & Immunity 2019, 20(5):436–446.
24.O’Byrne KJ, Dalgleish AG: Chronic immune activation and inflammation as the cause of malignancy. British journal of cancer 2001, 85(4):473–483.
25.Yu L-X, Ling Y, Wang H-Y: Role of nonresolving inflammation in hepatocellular carcinoma development and progression. npj Precision Oncology 2018, 2(1):6.
26.Shin E-C, Sung PS, Park S-H: Immune responses and immunopathology in acute and chronic viral hepatitis. Nature Reviews Immunology 2016, 16:509.
27.Sun P, Williams M, Nagabhushana N, Jani V, Defang G, Morrison BJ: NK Cells Activated through Antibody-Dependent Cell Cytotoxicity and Armed with Degranulation/IFN-γ Production Suppress Antibody-dependent Enhancement of Dengue Viral Infection. Scientific reports 2019, 9(1):1109.